Tresoda 420 mg/20 mL Concentrate for Infusion

Trastuzumab — HER2 Inhibitor (Anti-HER2 Targeted Therapy) for HER2-Positive Breast and Gastric Cancers

Prescription Only | IV Infusion Administered by a Healthcare Professional Only

Reviewed against FDA prescribing information and EMA SmPC for trastuzumab (Herceptin)

Manufactured by Incepta Pharmaceuticals Ltd | Last updated: June 2026 | Next scheduled review: June 2027 or upon label change

Trastuzumab’s defining safety feature, compared with most other cancer biologics, is that its main risk involves the heart rather than the gut, the blood, or the lungs first. That’s why cardiac function testing before and during treatment isn’t an optional precaution layered on top of standard care — it’s a structural part of how the FDA label requires trastuzumab to be used. Section 4 covers exactly what gets checked and when.

Note for publication: replace this section with a named, credentialed medical reviewer Dr. Salma Mamdouh Elreedy, MD, board-certified medical oncologist

1. What is Tresoda?

Tresoda is a cancer treatment. Its active ingredient is trastuzumab, a laboratory-made antibody that belongs to a drug class called HER2 inhibitors. Tresoda is manufactured by Incepta Pharmaceuticals Ltd, a Bangladesh-based manufacturer operating since 1999, using the same active ingredient as the originator brand, Herceptin.

Incepta is a large, diversified pharmaceutical manufacturer — by its own published figures, it produces over 1,300 generic presentations and exports to more than 100 countries — with international certifications across parts of its business, including EU GMP and UK MHRA approval for its solid-dosage facility and WHO prequalification for at least one injectable product line. It’s worth confirming directly with Incepta which specific facility produces Tresoda, and which accreditations apply to that facility and to this product specifically, since approval of one manufacturing site or product line is not the same as approval of every site or every product the company makes. As of this page’s last review, a published, product-specific accreditation record for Tresoda’s manufacturing site (as distinct from Incepta’s other facilities) was not identified in publicly available sources.

Trastuzumab works differently from traditional chemotherapy and differently from a hormone-blocking pill. It’s a large biologic molecule (an antibody), not a small chemical compound, and because of that it can only be given as an intravenous infusion — it cannot be made into a tablet.

A note on “generic” terminology for biologics: Unlike a small-molecule drug, a biologic like trastuzumab cannot be copied atom-for-atom by another manufacturer. When another company markets a version of an approved biologic, it’s typically reviewed by regulators as a biosimilar — a product shown through dedicated clinical and analytical studies to work the same way, with no clinically meaningful differences from the original.

Before relying on Tresoda, ask your pharmacist, oncologist, or Incepta Pharmaceuticals directly whether Tresoda has been reviewed and approved through your country’s biosimilar approval pathway, whether NCT06886659 has concluded and its results are available, and ask to see the specific regulatory approval and registration number. This page cannot confirm that status on your behalf — see Section 11 for what to ask and who to ask.

Who is Tresoda for?

Tresoda’s own manufacturer-published indication is HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction cancer, consistent with the originator brand’s core approved uses. Confirm with your oncologist and with Incepta directly which specific lines of therapy, treatment settings, and combination regimens Tresoda is registered for in your country, since a manufacturer can hold approval for one setting while a related setting remains unapproved for that specific product.

The table below shows the broader set of HER2-positive cancer settings approved for trastuzumab as an active ingredient generally, based on the originator brand’s label.

2. How does Tresoda work?

Some cancer cells, especially in certain breast and stomach cancers, have far more copies than normal of a receptor on their surface called HER2 (human epidermal growth factor receptor 2). Think of HER2 as a switch sitting on the outside of the cell. In a HER2-positive cancer, there are far too many of these switches, and they get flipped on too often, sending a constant “grow and divide” signal into the cell.

Trastuzumab works by attaching directly to the HER2 switch on the outside of the cancer cell, like a clamp that physically covers it so it can no longer be activated as easily. With the signal dampened, the cancer cell’s “grow and divide” instruction is interrupted. Trastuzumab also flags the cancer cell for the body’s own immune system, helping immune cells recognize and attack cells coated with the antibody.

This is why trastuzumab is described as a targeted, HER2-directed therapy rather than a classic chemotherapy drug. It only works in cancers confirmed to be HER2-positive, which is why HER2 testing is required before starting treatment, and it’s often used alongside chemotherapy or, in some settings, on its own.

3. How Tresoda is given

This is an infusion, not a tablet

Tresoda is given only as an intravenous (IV) infusion, through a vein, by a trained healthcare professional in an infusion center, oncology clinic, or hospital outpatient unit. You will never take Tresoda home, swallow it, or inject it yourself.

Infusion timing

Your exact dose in mg per kg of body weight, and how often you receive it, depends on which schedule your oncologist selects. Two general approaches are commonly used: a loading dose followed by treatment every 3 weeks, or a smaller weekly dose. Your oncology team will confirm your specific schedule and total planned duration of treatment — there is no single “standard dose” that applies to every patient or every cancer setting.

What happens during and after your infusion

• Your team will watch for any signs of an infusion reaction — fever, chills, nausea, breathing changes, low blood pressure — especially during your first infusion, when these reactions are most common.
• You’ll usually be asked to stay for a period of observation after the infusion finishes, particularly the first time.
• Your heart function will be checked before treatment starts and at regular intervals throughout, as described in Section 4.
• Tell your team immediately about any new shortness of breath, swelling, chest pain, cough, or unusual symptoms, even ones that seem minor.

If an infusion is delayed

Unlike a daily tablet, you don’t control the timing of an infusion yourself. If a scheduled infusion needs to be delayed — for example, because of a heart function result, an infection, or another safety concern — your oncology team will decide when it’s safe to resume. If a dose has been missed for an extended period, your team may need to restart with a loading dose rather than simply resuming the maintenance dose; this is a clinical decision, not something to manage yourself.

4. Monitoring and tests

Because trastuzumab’s most important risk involves the heart, your team will check your heart function on a structured schedule throughout treatment, not only if you develop symptoms.

5. Dose adjustments

Trastuzumab dosing is calculated by your body weight (mg per kg) rather than using a fixed set of dose-reduction steps like some tablet therapies. If side effects occur, your oncologist generally manages them in one of these ways, depending on severity:

You won’t be the one calculating any of these numbers — that’s your oncology team’s job, using your echocardiogram or MUGA scan results. This table is here so you understand what they’re looking at and why a hold or stop decision gets made the way it does.

Never adjust the timing or decide to skip a dose yourself. Because Tresoda is given by infusion, these decisions are made entirely by your oncology team based on your heart function results and symptoms.

6. Boxed warning: the risks the FDA highlights most

This section covers the risks placed in trastuzumab’s boxed warning, the FDA’s strongest level of safety alert. Please read this before your first infusion.

Cardiomyopathy (heart failure)

• The risk: Both silent declines in heart pumping function and clinical heart failure, including congestive heart failure (CHF) and a drop in left ventricular ejection fraction (LVEF).
• How common: Depends heavily on what else you’re being treated with. As trastuzumab alone (no anthracycline chemotherapy), cardiac dysfunction has occurred in roughly 3% to 7% of patients across pivotal trials, with symptomatic heart failure generally under 4%. Given at the same time as anthracycline chemotherapy (such as doxorubicin), cardiac dysfunction has been reported as high as 27% to 28% in some trial arms, with severe (NYHA class III or IV) heart failure in up to about 19%.
• Why it matters: This is the clearest reason trastuzumab is generally not given concurrently with anthracyclines. Most cardiac dysfunction improves after the drug is stopped, but treatment is generally discontinued if clinically significant heart failure develops. Your heart function is checked before treatment starts and at regular intervals throughout — see Section 4.

Infusion reactions and pulmonary toxicity

• The risk: Serious and occasionally fatal infusion reactions and lung problems, including anaphylaxis, angioedema (swelling), interstitial pneumonitis (lung inflammation), and acute respiratory distress syndrome (ARDS).
• When it happens: Symptoms most often occur during the infusion or within 24 hours afterward.
• Why it matters: Your team is trained to watch for these reactions, especially with your first dose, and treatment is permanently stopped if a severe reaction or significant lung toxicity occurs.

Embryo-fetal toxicity

• The risk: Serious harm to a developing baby if given during pregnancy, including a condition called oligohydramnios (low amniotic fluid), which in some reported cases has been associated with underdeveloped lungs in the baby, skeletal problems, and newborn death.
• The requirement: Effective contraception during treatment and for a period after the last dose — see Section 9 for details.
• What to do: Tell your oncology team immediately if you are pregnant, think you might be pregnant, or become pregnant during treatment.

7. Other side effects

Very common

• Fever and chills, especially with the first infusion
• Nausea and vomiting
• Diarrhea
• Fatigue and weakness
• Headache
• Infections, including upper respiratory tract infections
• Increased cough
• Rash
• Muscle and joint pain (myalgia)
• Asymptomatic decline in heart pumping function (LVEF) — reported in roughly 1 in 10 patients in some trials, which is why heart scans continue throughout treatment even if you feel completely well

Serious side effects — seek immediate medical attention

• Heart failure symptoms: new or worsening shortness of breath, cough, swelling in the legs or ankles, sudden weight gain, or a fast or irregular heartbeat.
• Severe infusion reactions: difficulty breathing, swelling of the face, lips, or throat, wheezing, or a sharp drop in blood pressure during or shortly after the infusion. Your team is trained to treat this immediately.
• Lung problems: new or worsening shortness of breath, especially if it comes on suddenly, can signal interstitial pneumonitis or ARDS, particularly in patients with pre-existing lung disease.
• Low white blood cell counts (neutropenia), particularly when trastuzumab is combined with chemotherapy: increased risk of fever and infection.
• Severe diarrhea: ongoing or severe diarrhea should be reported, as it can lead to dehydration.

8. Surgery, other medicines, and situations to flag

Trastuzumab isn’t broken down by the liver enzyme system the way many tablet cancer drugs are, so it doesn’t carry the same long list of drug-interaction warnings. Instead, the most important precautions relate to your heart health and to other medicines that also affect the heart.

Always tell your oncologist and pharmacist about every medicine, supplement, and herbal product you take, including over-the-counter remedies, and update this list at every visit.

9. Special populations

10. Clinical evidence

Trastuzumab’s approval across HER2-positive breast and gastric cancers is supported by multiple Phase 3 clinical trials reviewed by the FDA and the European Medicines Agency. A few headline examples:

11. Generic biologic vs. brand: what’s the same, what’s different, and what to ask

Tresoda contains the same active ingredient, trastuzumab, as the originator brand, Herceptin. But because trastuzumab is a biologic (a complex molecule made using living cells, not a simple chemical), “same active ingredient” means something a little different here than it would for a tablet.

If you’re considering switching between Tresoda and Herceptin, or starting either for the first time, discuss this with your oncologist so your monitoring plan and treatment records, especially your heart function tracking, stay consistent and clearly documented.

12. How Tresoda is sourced and verified

Trastuzumab is never available over the counter, at a retail pharmacy counter, or as a vial delivered to a patient’s home for self-administration. It’s a cold-chain biologic that must stay continuously refrigerated and is only safe to use when it’s reconstituted and prepared by a pharmacist immediately before your infusion. Because of this, “sourcing” Tresoda is fundamentally a clinical supply-chain task, not a patient purchasing task — your role is to ask the right questions, not to place an order yourself.

This isn’t a theoretical concern. Counterfeit trastuzumab has reached real patients: in 2014, the European Medicines Agency issued an alert after stolen Herceptin vials, tampered with and re-introduced into the legitimate supply chain, were found circulating in EU member states. More recently, Nigeria’s drug regulator flagged a counterfeit batch of Herceptin in 2025 after a patient in Ghana presented with a vial bearing a batch number that didn’t correspond to any product Roche had actually manufactured. Counterfeit vials in past incidents have been found to contain no active ingredient at all, or a diluted version unlikely to provide any clinical benefit.

Generic Oncology is an online platform that helps oncology centers, hospital pharmacies, and treatment coordinators source and verify generic and biosimilar oncology medicines, including Tresoda, with batch-level traceability back to Incepta Pharmaceuticals. The platform itself is built around clinical and pharmacy-side procurement, not direct-to-patient delivery — a vial of Tresoda ordered through it still travels through your treatment center’s pharmacy and cold-chain handling before it ever reaches you, in the same way it would if sourced through any other verified channel.

Here’s what this means for you as a patient, and what’s worth asking:

• Ask your oncology team whether their pharmacy sources Tresoda through Generic Oncology or another verified channel. You’re entitled to know where your medicine comes from, even though you won’t be the one ordering or receiving it directly.
• Ask about batch/lot traceability. A platform like Generic Oncology should be able to provide your treatment center with a batch number traceable back to Incepta Pharmaceuticals for every vial. If you ever have a reaction or a question, this batch number matters for your medical record and for any safety reporting.
• Confirm the order is going through your treatment center’s pharmacy, not to you directly. A legitimate sourcing platform for an IV cold-chain biologic coordinates with hospitals and clinics; it should never ship a vial of Tresoda to a patient’s home address for self-administration or personal transport. If anyone, including a platform representative, suggests otherwise, treat it as a serious red flag and raise it with your oncologist immediately.
• Verify registration independently if you have any doubt. Contact Incepta Pharmaceuticals directly, or check with your national medicines regulator (for example, the FDA in the United States, the EMA in the European Union, or your country’s equivalent body) to confirm both Tresoda’s and the sourcing platform’s standing before treatment begins.
• Never accept or personally purchase an injectable cancer biologic from any seller, online or otherwise, that bypasses your treatment center’s pharmacy. Counterfeit or improperly stored biologic cancer drugs are a real and serious risk, since these products can lose effectiveness or become unsafe if mishandled at any point in the cold chain, and that risk is impossible for a patient to detect on their own.

13. How Tresoda is stored

Storage and handling of Tresoda is managed entirely by your hospital or infusion center’s pharmacy, not by you at home. For reference:

• Stored refrigerated (typically 2°C to 8°C / 36°F to 46°F), protected from light, prior to reconstitution.
• Not frozen.
• Reconstituted and diluted by trained pharmacy staff shortly before your infusion, following the manufacturer’s specific reconstitution instructions.
• Any unused vial or reconstituted solution is discarded according to cytotoxic pharmaceutical waste guidance, not household disposal.

14. Patient FAQ

Medical Disclaimer

The information on this page is for educational purposes and does not constitute medical advice. Tresoda must be prescribed, administered, and supervised exclusively by a qualified medical oncology team within a clinical infusion setting. Treatment decisions should always be made in consultation with your healthcare team based on your individual clinical situation, cancer type, HER2 status, and stage. This page was prepared using FDA prescribing information and EMA SmPC data for trastuzumab; consult the current full prescribing information for complete details.

Reporting side effects: If you experience a side effect, tell your oncologist or pharmacist. You can also report suspected side effects directly to your national regulatory authority (for example, the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch in the United States, or your country’s medicines regulator).